Monopar Therapeutics (MNPR) Free Cash Flow (2017 - 2025)

Monopar Therapeutics has disclosed Free Cash Flow across 9 years of filings, most recently posting -$3.4 million for Q4 2025.

• Free Cash Flow for Q4 2025 came in at -$3.4 million, down 68.64% year-over-year; the trailing twelve-month figure through Dec 2025 was -$12.2 million (down 90.52% YoY), and the FY2025 annual result was -$12.2 million, down 90.52% from the prior year.
• Free Cash Flow came in at -$3.4 million for Q4 2025 at Monopar Therapeutics, down from -$2.1 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of -$1.1 million in Q3 2024 to a low of -$5.7 million in Q1 2025.
• The 5-year median for Free Cash Flow is -$1.9 million (2021), against an average of -$2.1 million.
• Across the five-year window, Free Cash Flow jumped 44.66% in 2024 and plunged 242.11% in 2025, its largest moves.
• Monopar Therapeutics' Free Cash Flow stood at -$2.0 million in 2021, then surged by 35.93% to -$1.3 million in 2022, then fell by 18.75% to -$1.5 million in 2023, then dropped by 29.27% to -$2.0 million in 2024, then tumbled by 68.64% to -$3.4 million in 2025.
• The last three Free Cash Flow figures came in at -$3.4 million (Q4 2025), -$2.1 million (Q3 2025), and -$1.1 million (Q2 2025), per Business Quant data.